Bonafide Acquires MSI-195 SAM-e Nutritional Technology from Methylation Sciences

Pharmavite Acquires Bonafide Health for $425 Million

November 30, 2023

Consumer Products

Pharmavite LLC has acquired Bonafide Health for $425 million, expanding its women's health portfolio alongside brands such as Uqora and Equelle. Bonafide Health will continue to operate from its Harrison, New York headquarters and the deal strengthens Pharmavite's position in science-backed nutraceuticals for menopause and women's health.

Charles River Laboratories Acquires SAMDI Tech

January 30, 2023

Biotechnology

Charles River Laboratories acquired the remaining 80% stake in SAMDI Tech for $50 million in cash, completing a transaction that follows a partnership begun in 2018. The acquisition integrates SAMDI Tech's proprietary mass spectrometry high-throughput screening technology into Charles River's Discovery and Safety Assessment segment to strengthen drug discovery capabilities and accelerate hit identification for pharmaceutical and biotech clients.

WellSky Acquires Bonafide

November 19, 2024

Healthcare Services

WellSky has acquired Bonafide, a Thousand Oaks–based provider of enterprise software for durable/home medical equipment (DME/HME) companies. The deal expands WellSky's footprint in the DME/HME market by integrating Bonafide's ERP, billing and revenue-cycle capabilities into WellSky's home-care and post-acute solutions.

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

Shin Nippon Biomedical Laboratories Acquires Satsuma Pharmaceuticals

April 16, 2023

Biotechnology

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) has entered into a definitive agreement to acquire all outstanding shares of Satsuma Pharmaceuticals for $0.91 per share in cash plus a non-tradeable contingent value right (CVR) of up to $5.77 per share tied to future monetization of STS101. The transaction gives SNBL ownership of Satsuma's investigational intranasal migraine product STS101 and associated delivery technology, and is supported by Satsuma’s board as maximizing value for stockholders.

DCA Partners Invests in Bonafide Medical Group

November 29, 2021

Healthcare Services

DCA Partners has made a growth investment in Bonafide Medical Group to support product development and expand distribution of Bonafide’s cloud-based ERP and facility portal for DME, acute care, and long-term care providers. Bonafide, based in Thousand Oaks, California, will work with DCA to extend software features and leverage the firm’s SaaS experience to accelerate growth.